CN112941029A - 一种双向抗体重组的外泌体及其制备方法 - Google Patents
一种双向抗体重组的外泌体及其制备方法 Download PDFInfo
- Publication number
- CN112941029A CN112941029A CN202011620768.0A CN202011620768A CN112941029A CN 112941029 A CN112941029 A CN 112941029A CN 202011620768 A CN202011620768 A CN 202011620768A CN 112941029 A CN112941029 A CN 112941029A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cells
- exosome
- bidirectional
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公布了一种双向抗体重组的外泌体,该外泌体为CAR‑Exos,其包括有两种抗体,其中一个为具有遗传编码的抗人CD3抗体,另一个为具有遗传编码的抗人CD38抗体,本发明还公布了一种双向抗体重组的外泌体的制备方法,包括以下制作步骤:步骤一:每50mL细胞需要准备50μg pDisplay‑CD3 scfv‑CD38 nanobody质粒,用2mL Opti‑MEM培养基稀释质粒,混匀后静置5分钟;与现有技术相比,本发明的有益效果是:产生的双重靶向T细胞CD3和CD38受体的CAT‑Exos可以将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中,达到靶向治疗的目的。
Description
技术领域
本发明涉及基因技术领域,具体为一种双向抗体重组的外泌体及其制备方法。
背景技术
CAR-T细胞疗法是指将经过设计的CAR-T细胞可在实验室培养生长,达到数十亿之多将扩增后的CAR-T细胞注入到患者体内,注入之后的T细胞也会在患者体内增殖,并杀死具有相应特异性抗原的肿瘤细胞。CAR是一种蛋白质受体,可使T细胞识别肿瘤细胞表面的特定蛋白质(抗原),表达CAR的T细胞可识别并结合肿瘤抗原,进而攻击肿瘤细胞。这种表达CAR的T细胞被称为CAR-T。
表达嵌合抗原受体(CAR)的基因工程T细胞作为一种最有希望的针对血液恶性肿瘤的新治疗方法。但CAR-T疗法可引起快速而持久的临床反应,CAR-T细胞易受免疫抑制机制的影响,本专利提出一种名为双向抗体重组的外泌体(CAR-Exo)的开发,该外体作为细胞免疫的调节剂,可重新定向免疫效应细胞并控制其免疫反应性。。
发明内容
本发明的目的在于提供一种双向抗体重组的外泌体及其制备方法,以解决背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:一种双向抗体重组的外泌体,该外泌体为CAR-Exos,其包括有两种抗体,其中一个为具有遗传编码的抗人CD3抗体,另一个为具有遗传编码的抗人CD38抗体。
优选的,类血小板源性生长因子受体的跨膜域作为融合靶蛋白在外泌体CAR-Exos表面展示CD3抗体和CD38抗体。
优选的,该外泌体CAR-Exos用于治疗多发性多发骨髓瘤。
优选的,该外泌体CAR-Exos将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中。
一种双向抗体重组的外泌体的制备方法,包括以下制作步骤:
步骤一:每50mL细胞需要准备50μg pDisplay-CD3 scfv-CD38nanobody质粒,用2mL Opti-MEM培养基稀释质粒,混匀后静置5分钟;
步骤二:每50mL细胞需要准备100μL PEI试剂,用2mL Opti-MEM培养基稀释,混匀后静置5分钟;
步骤三:将步骤一、步骤二中试剂混匀静置15分钟;
步骤四:3.将试剂加入细胞中,混匀,放置于轨道摇床置于≥80%相对湿度和8%CO2的37℃培养箱内进行培养
步骤五:72h后收集外泌体;
步骤六:收获的细胞培养的上清液体含有将外泌体在4℃下以100×g离心10分钟,并以4000×g,离心30分钟,然后14000×g保持50分钟;
步骤七:然后收集上清液然后使用0.2μm注射器过滤器过滤后的上清在超高速离心转子中以200,000×g离心2小时;
步骤八:倒出上清液后,获得纯化后的外泌体。
与现有技术相比,本发明的有益效果是:产生的双重靶向T细胞CD3和CD38受体的CAT-Exos可以将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中,达到靶向治疗的目的。
附图说明
图1为本发明的外泌体结构示意图。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明提供一种技术方案:一种双向抗体重组的外泌体,该外泌体为CAR-Exos,其包括有两种抗体,其中一个为具有遗传编码的抗人CD3抗体,另一个为具有遗传编码的抗人CD38抗体。
其中,CD3抗体的全长蛋白序列为:
MDIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSKFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFAGGTKLEIKGGGGSGGGGSGGGGSEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWMGLINPYKGVSTYNQKFKDKATLTVDKSSSTAYMELLSLTSEDSAVYYCARSGYYGDSDWYFDVWGQGTTLTVFSGGGGSSSSGGGGSSSSGGGGSSSSPRDVQLQESGGGLVQAGGSLRLSCTGSGRTFRNYPMAWFRQAPGKEREFVAGITWVGASTLYADFAKGRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAGRGIVAGRIPAEYADWGQGTQVTVSS。
CD38抗体的全长DNA序列为:
ATGGACATCCAGATGACCCAGACCACCAGCTCCCTCAGCGCCTCCCTCGGCGACAGAGTGACAATTAGCTGTAGAGCCAGCCAGGACATCAGAAACTACCTGAACTGGTATCAGCAAAAACCCGACGGCACAGTGAAGCTGCTGATCTACTACACCAGCAGACTGCACAGCGGTGTGCCCAGCAAGTTCTCAGGCTCTGGCAGCGGGACTGATTACAGCCTGACCATCAGCAATCTGGAACAGGAGGATATCGCCACCTACTTCTGCCAGCAGGGGAATACACTGCCTTGGACCTTTGCCGGCGGCACCAAGCTGGAAATCAAGGGCGGCGGCGGCTCCGGCGGCGGCGGAAGCGGCGGAGGCGGAAGCGAGGTGCAGCTGCAACAAAGCGGCCCTGAGCTGGTGAAACCAGGAGCCTCTATGAAAATCAGCTGCAAGGCCAGCGGCTACAGCTTCACCGGATACACAATGAACTGGGTCAAGCAGAGCCACGGAAAGAACCTGGAATGGATGGGCCTGATCAACCCTTACAAGGGAGTGAGCACATACAACCAGAAGTTTAAGGACAAGGCAACACTGACCGTGGACAAGTCCTCCTCGACCGCCTACATGGAACTGCTGTCACTGACATCTGAGGATTCTGCCGTGTACTACTGCGCCAGAAGCGGCTATTACGGCGATAGCGACTGGTACTTCGACGTTTGGGGCCAGGGCACGACCCTGACAGTCTTTAGCGGCGGCGGAGGCTCCTCTTCTAGCGGCGGCGGAGGTTCGAGCAGCTCTGGCGGAGGCGGCTCTAGCAGCTCCCCGCGGGATGTGCAGCTGCAGGAGAGCGGCGGCGGACTGGTGCAGGCCGGAGGCAGCCTGCGGCTGAGCTGCACCGGCAGCGGCAGGACCTTCCGGAACTACCCTATGGCCTGGTTCAGACAGGCTCCTGGCAAGGAAAGAGAGTTCGTGGCTGGCATCACCTGGGTGGGCGCTTCTACCCTGTACGCTGACTTCGCTAAAGGCAGATTCACCATCAGCCGGGACAACGCCAAGAATACCGTGTACCTGCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTATTCTTGTGCCGCCGGCCGAGGAATCGTGGCCGGCCGGATCCCTGCCGAGTACGCCGATTGGGGCCAGGGCACACAGGTGACAGTGTCCAGC
类血小板源性生长因子受体的跨膜域作为融合靶蛋白在外泌体CAR-Exos表面展示CD3抗体和CD38抗体。
该外泌体CAR-Exos用于治疗多发性多发骨髓瘤。
该外泌体CAR-Exos将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中。
一种双向抗体重组的外泌体的制备方法,包括以下制作步骤:
步骤一:每50mL细胞需要准备50μg pDisplay-CD3 scfv-CD38nanobody质粒,用2mL Opti-MEM培养基稀释质粒,混匀后静置5分钟;
步骤二:每50mL细胞需要准备100μL PEI试剂,用2mL Opti-MEM培养基稀释,混匀后静置5分钟;
步骤三:将步骤一、步骤二中试剂混匀静置15分钟;
步骤四:3.将试剂加入细胞中,混匀,放置于轨道摇床置于≥80%相对湿度和8%CO2的37℃培养箱内进行培养
步骤五:72h后收集外泌体;
步骤六:收获的细胞培养的上清液体含有将外泌体在4℃下以100×g离心10分钟,并以4000×g,离心30分钟,然后14000×g保持50分钟;
步骤七:然后收集上清液然后使用0.2μm注射器过滤器过滤后的上清在超高速离心转子中以200,000×g离心2小时;
步骤八:倒出上清液后,获得纯化后的外泌体。
本专利提出一种名为双向抗体重组的外泌体(CAR-Exo)的开发,该外体作为细胞免疫的调节剂,可重新定向免疫效应细胞并控制其免疫反应性。通过在基因工程方法在外泌体上同时展示两种类型的抗体,其中一种抗体能特异针对人T细胞表面的CD3,另外一个纳米抗体(nanobody)特异识别多发性多发骨髓瘤的表面蛋白CD38,这样一种CAR-Exo同时结合T细胞表面和癌细胞,我们证明在体外和体内具有很高的抗癌免疫力。
如图1,创新性设计了的CAR-Exos,在外泌体表面具有遗传编码的抗人CD3和抗人CD38抗体。结果显示,产生的双重靶向T细胞CD3和CD38受体的CAT-Exos不仅可以将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中。重要的是,使用小鼠异种移植模型的体内研究表明,CAR-Exos具有出色的抗肿瘤活性。
与CAR-T细胞相比,CAR外泌体不表达程序性细胞死亡蛋白1(PD1)。与CAR-T疗法相比,本发明专利通过创新设计的CAR外泌体的给药相对安全。这项研究支持将外泌体用作仿生纳米囊泡。具有很好的市场应用前景,具有较好的普及前景,对于医疗上面有重要的意义。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (5)
1.一种双向抗体重组的外泌体,其特征在于:该外泌体为CAR-Exos,其表面包括有两种抗体,其中一个为具有遗传编码的抗人CD3抗体,另一个为具有遗传编码的抗人CD38抗体。
2.根据权利要求1所述的一种双向抗体重组的外泌体,其特征在于:类血小板源性生长因子受体的跨膜域作为融合靶蛋白在外泌体CAR-Exos表面展示CD3抗体和CD38抗体。
3.根据权利要求1所述的一种双向抗体重组的外泌体,其特征在于:该外泌体CAR-Exos用于治疗多发性多发骨髓瘤。
4.根据权利要求3所述的一种双向抗体重组的外泌体,其特征在于:该外泌体CAR-Exos将人T细胞募集到CD38阳性多发性多发骨髓瘤细胞中。
5.一种权利要求1-4任意一项所述的双向抗体重组的外泌体的制备方法,其特征在于,包括以下制作步骤:
步骤一:每50mL细胞需要准备50μg pDisplay-CD3 scfv-CD38 nanobody质粒,用2mLOpti-MEM培养基稀释质粒,混匀后静置5分钟;
步骤二:每50mL细胞需要准备100μL PEI试剂,用2mL Opti-MEM培养基稀释,混匀后静置5分钟;
步骤三:将步骤一、步骤二中试剂混匀静置15分钟;
步骤四:3.将试剂加入细胞中,混匀,放置于轨道摇床置于≥80%相对湿度和8%CO2的37℃培养箱内进行培养
步骤五:72h后收集外泌体;
步骤六:收获的细胞培养的上清液体含有将外泌体在4℃下以100×g离心10分钟,并以4000×g,离心30分钟,然后14000×g保持50分钟;
步骤七:然后收集上清液然后使用0.2μm注射器过滤器过滤后的上清在超高速离心转子中以200,000×g离心2小时;
步骤八:倒出上清液后,获得纯化后的外泌体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011620768.0A CN112941029A (zh) | 2020-12-31 | 2020-12-31 | 一种双向抗体重组的外泌体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011620768.0A CN112941029A (zh) | 2020-12-31 | 2020-12-31 | 一种双向抗体重组的外泌体及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112941029A true CN112941029A (zh) | 2021-06-11 |
Family
ID=76235042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011620768.0A Pending CN112941029A (zh) | 2020-12-31 | 2020-12-31 | 一种双向抗体重组的外泌体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112941029A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114438038A (zh) * | 2022-01-30 | 2022-05-06 | 浙江大学医学院附属邵逸夫医院 | N-钙黏素多肽修饰间充质干细胞源性外泌体的制备和应用 |
-
2020
- 2020-12-31 CN CN202011620768.0A patent/CN112941029A/zh active Pending
Non-Patent Citations (5)
Title |
---|
AN 等: "Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.", 《MOL. PHARMACEUTICS》 * |
CHU 等: "Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma.", 《BLOOD》 * |
FU ET AL.: "CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.", 《NATURE COMMUNICATIONS》 * |
XIANG-JUN TANG 等: "Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.", 《ONCOTARGET》 * |
ZAFRA 等: "Preclinical Characterization of AMG 424, a Novel Humanized T Cell-Recruiting Bispecific Anti-CD3/CD38 Antibody.", 《BLOOD》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114438038A (zh) * | 2022-01-30 | 2022-05-06 | 浙江大学医学院附属邵逸夫医院 | N-钙黏素多肽修饰间充质干细胞源性外泌体的制备和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2577226C2 (ru) | Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих | |
CN110317822B (zh) | Trop2嵌合抗原受体、其t细胞及其制备方法和用途 | |
CN102526716A (zh) | 一种特异性肿瘤杀伤细胞的制备 | |
CN114349845B (zh) | 一种促进t淋巴细胞的肿瘤浸润性的外泌体及其制备方法 | |
WO2009139413A1 (ja) | サイトカイン誘導キラー細胞含有細胞集団の製造方法 | |
CN105647865A (zh) | 同时制备抗肿瘤的联合免疫细胞dc-cik、nk的方法及制得的联合免疫细胞 | |
CN112625142B (zh) | Cxcl9修饰的car-t结构及其应用 | |
CN102199218A (zh) | 一种抗Her2抗体-白细胞介素2融合蛋白及其用途 | |
CN112941029A (zh) | 一种双向抗体重组的外泌体及其制备方法 | |
CN113528436B (zh) | 基于淋巴细胞的同源靶向性人工抗原呈递细胞及其构建和应用 | |
CN117025530B (zh) | 用肿瘤坏死因子受体超家族激动剂扩增肿瘤浸润淋巴细胞(til)的方法 | |
CN107858352B (zh) | 一种shRNA-cluster序列及其表达载体和用途 | |
US20220177839A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
CN111420031A (zh) | 一种经基因工程改造的抗肿瘤微颗粒的制备方法及应用 | |
CN114672457A (zh) | 来源于肿瘤组织的具有肿瘤特异性杀伤效果的t淋巴细胞及其制备方法和细胞制剂 | |
CN106565828B (zh) | 诱导dc-cik细胞的多肽及其在肿瘤细胞治疗中的应用 | |
CN115094035A (zh) | 一种体外扩增诱导t细胞为组织定居记忆性t细胞的方法 | |
CN115029320A (zh) | 用于肿瘤放疗增敏的工程化外泌体、制备方法、应用 | |
EP0251107A2 (en) | Improved fusion products | |
CN117143815B (zh) | 工程化记忆样nk细胞的制备方法及应用 | |
CN116606884B (zh) | 一种制备car-t细胞的方法以及制得的car-t细胞及其应用 | |
CN116555188B (zh) | 一种抗pd-1双靶点的car-nk细胞及其应用 | |
CN115944650B (zh) | 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法 | |
CN115992142B (zh) | 与神经保护相关的hsa_circ_0000288及用途 | |
WO2022242359A1 (zh) | 一种体液免疫系统再生的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210611 |
|
RJ01 | Rejection of invention patent application after publication |